First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis

AIMS: To assess safety, pharmacokinetics (PK) and clinical efficacy of bimekizumab (formerly UCB4940), a novel humanized monoclonal antibody and dual inhibitor of interleukin (IL)‐17A and IL‐17F, in subjects with mild plaque psoriasis. METHODS: Randomized, double‐blind, first‐in‐human study of bimek...

Full description

Saved in:
Bibliographic Details
Published in:Br J Clin Pharmacol
Main Authors: Glatt, Sophie, Helmer, Eric, Haier, Birgit, Strimenopoulou, Foteini, Price, Graham, Vajjah, Pavan, Harari, Olivier A., Lambert, John, Shaw, Stevan
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2017
Subjects:
Clinical Trials
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5401985/
https://ncbi.nlm.nih.gov/pubmed/27859546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13185
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items